Granules India Ltd. — Capital/Financing Update 2020

Jul 2, 2020

==> picture [150 x 45] intentionally omitted <==

REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad – 500 081, Telangana, INDIA. Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com CIN: L24110TG1991PLC012471

Dated July 02, 2020

To, National Stock Exchange of India Limited BSE Limited Symbol: NSE: GRANULES; BSE: 532482

Sub: Press Release

Dear Sir,

We are herewith enclosing the press release given by the Company.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours sincerely,

For GRANULES INDIA LIMITED

==> picture [83 x 84] intentionally omitted <==

CHAITANYA TUMMALA (COMPANY SECRETARY & COMPLIANCE OFFICER) Encl as above

==> picture [159 x 47] intentionally omitted <==

Press Release

Release of Pledge on the company's shares

Hyderabad, July 2, 2020

Dear Sir/Madam,

With reference to communication dated June 30, 2020 regarding reduction of Pledge on shares held by the promoter of Granules India Limited (GIL).

As per the said communication, the promoters have informed that they have reduced 12.95% of the total equity share pledge on GIL. Post this event, 3.64% of the total shareholder’s equity is still currently pledged.

In this regard, Mr Krishna Prasad Chigurupati Chairman and Managing Director said "As communicated earlier, I am in line with the timelines committed to reduce my pledge of shares. The pledge was made earlier to fund the share warrants that were taken to fund the Capex of the company. I will be clearing the rest shortly and will remain committed to future growth and development of Granules and remain bullish about our business ability to create long-term shareholders value”.

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India is a growing pharmaceutical manufacturing company with best in class facilities and is committed to operational excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) which gives the customers flexibility and choice. Granules support customers with unique value, extensive product range, and proactive solutions. The Company’s global presence extends to over 250 customers in 60 countries through offices in India, U.S., and U.K. The Company has 6 manufacturing facilities out of which 5 are in India and 1 in USA and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC and HALAL

Contacts: Sandip Neogi Chaitanya Tummala Chief Financial Officer Company Secretary 040-30663573 040-30663614 sandip.neogi@granulesindia.com chaitanya.tummala@granulesindia.com

Safe Harbour

This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological and/or regulatory factors. Granules India Ltd., its directors and any of the affiliates or employee is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

CIN: L24110TG1991PLC012471 / Granules India Limited: 2nd Floor, Block 3, My home hub Madhapur, Hyderabad 500081